142 related articles for article (PubMed ID: 37333829)
1. Combination of C-reactive protein/albumin ratio and time to castration resistance enhances prediction of prognosis for patients with metastatic castration-resistant prostate cancer.
Mitsui Y; Yamabe F; Hori S; Uetani M; Aoki H; Sakurabayashi K; Okawa M; Kobayashi H; Nagao K; Nakajima K
Front Oncol; 2023; 13():1162820. PubMed ID: 37333829
[TBL] [Abstract][Full Text] [Related]
2. Impact of Time to Castration Resistance on Survival in Metastatic Hormone Sensitive Prostate Cancer Patients in the Era of Combination Therapies.
Wenzel M; Preisser F; Hoeh B; Schroeder M; Würnschimmel C; Steuber T; Heinzer H; Banek S; Ahrens M; Becker A; Karakiewicz PI; Chun FKH; Kluth LA; Mandel P
Front Oncol; 2021; 11():659135. PubMed ID: 33968764
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Significance of Time to Castration Resistance in Patients With Metastatic Castration-sensitive Prostate Cancer.
Miyake H; Matsushita Y; Watanabe H; Tamura K; Motoyama D; Ito T; Sugiyama T; Otsuka A
Anticancer Res; 2019 Mar; 39(3):1391-1396. PubMed ID: 30842173
[TBL] [Abstract][Full Text] [Related]
4. C reactive protein/Albumin ratio as predictor of prognosis in castration resistant metastatic prostate cancer.
Lorigo J; Tavares Silva E; Pedroso Lima J; Quaresma V; Pedrosa R; Figueiredo A
Arch Ital Urol Androl; 2023 Jul; 95(3):11242. PubMed ID: 37435750
[TBL] [Abstract][Full Text] [Related]
5. Whole blood
Kwan EM; Fettke H; Crumbaker M; Docanto MM; To SQ; Bukczynska P; Mant A; Ng N; Foroughi S; Graham LK; Haynes AM; Azer S; Lim LE; Segelov E; Mahon K; Davis ID; Parente P; Pezaro C; Todenhöfer T; Sathianathen N; Hauser C; Horvath LG; Joshua AM; Azad AA
Transl Androl Urol; 2021 Apr; 10(4):1688-1699. PubMed ID: 33968657
[TBL] [Abstract][Full Text] [Related]
6. Is the duration of castration resistance predictive for sequential treatment responses in the metastatic castration-resistant prostate cancer setting?
Dülgar Ö; Özyükseler DT; Başak M; Ay S; Tural D; Yıldırım ME; Gümüş M
J Oncol Pharm Pract; 2021 Sep; 27(6):1388-1394. PubMed ID: 32847482
[TBL] [Abstract][Full Text] [Related]
7. A retrospective study on the prognostic value of preoperative C-reactive protein to albumin ratio in patients with oral cavity squamous cell carcinoma.
Fang KH; Lai CH; Hsu CM; Huang E; Tsai MS; Chang GH; Lee YC; Tsai YT
PeerJ; 2020; 8():e9361. PubMed ID: 32587804
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of C-Reactive Protein, Glasgow Prognostic Score, and C-Reactive Protein-to-Albumin Ratio in Colorectal Cancer.
Zhou J; Wei W; Hou H; Ning S; Li J; Huang B; Liu K; Zhang L
Front Cell Dev Biol; 2021; 9():637650. PubMed ID: 34765598
[No Abstract] [Full Text] [Related]
9. Prognostic impact of C-reactive protein-albumin ratio for the lethality in castration-resistant prostate cancer.
Uchimoto T; Komura K; Fujiwara Y; Saito K; Tanda N; Matsunaga T; Ichihashi A; Tsutsumi T; Tsujino T; Yoshikawa Y; Nishimoto Y; Takai T; Minami K; Taniguchi K; Tanaka T; Uehara H; Hirano H; Nomi H; Ibuki N; Takahara K; Inamoto T; Azuma H
Med Oncol; 2019 Nov; 37(1):9. PubMed ID: 31754918
[TBL] [Abstract][Full Text] [Related]
10. Sequencing impact and prognostic factors in metastatic castration-resistant prostate cancer patients treated with cabazitaxel: A systematic review and meta-analysis.
Yanagisawa T; Kawada T; Rajwa P; Mostafaei H; Motlagh RS; Quhal F; Laukhtina E; König F; Pallauf M; Pradere B; Karakiewicz PI; Nyirady P; Kimura T; Egawa S; Shariat SF
Urol Oncol; 2023 Apr; 41(4):177-191. PubMed ID: 35970698
[TBL] [Abstract][Full Text] [Related]
11. Bone Scan Index as an Imaging Biomarker in Metastatic Castration-resistant Prostate Cancer: A Multicentre Study Based on Patients Treated with Abiraterone Acetate (Zytiga) in Clinical Practice.
Reza M; Ohlsson M; Kaboteh R; Anand A; Franck-Lissbrant I; Damber JE; Widmark A; Thellenberg-Karlsson C; Budäus L; Steuber T; Eichenauer T; Wollmer P; Edenbrandt L; Trägårdh E; Bjartell A
Eur Urol Focus; 2016 Dec; 2(5):540-546. PubMed ID: 28723520
[TBL] [Abstract][Full Text] [Related]
12. Pattern of Clinical Progression Until Metastatic Castration-Resistant Prostate Cancer: An Epidemiological Study from the European Prostate Cancer Registry.
Verry C; Vincendeau S; Massetti M; Blachier M; Vimont A; Bazil ML; Bernardini P; Pettré S; Timsit MO
Target Oncol; 2022 Jul; 17(4):441-451. PubMed ID: 35841526
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of an inflammatory index for patients with metastatic castration-resistant prostate cancer.
Yamada Y; Sakamoto S; Rii J; Yamamoto S; Kamada S; Imamura Y; Nakamura K; Komiya A; Nakatsu H; Ichikawa T
Prostate; 2020 May; 80(7):559-569. PubMed ID: 32134137
[TBL] [Abstract][Full Text] [Related]
14. Which Factors Predict Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Post-Docetaxel?
Van Praet C; Rottey S; Van Hende F; Pelgrims G; Demey W; Van Aelst F; Wynendaele W; Gil T; Schatteman P; Filleul B; Schallier D; Machiels JP; Schrijvers D; Everaert E; D'Hondt L; Werbrouck P; Vermeij J; Mebis J; Clausse M; Rasschaert M; Van Erps J; Verheezen J; Van Haverbeke J; Goeminne JC; Lumen N
Clin Genitourin Cancer; 2017 Aug; 15(4):502-508. PubMed ID: 28258960
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer.
Kwan EM; Fettke H; Docanto MM; To SQ; Bukczynska P; Mant A; Pook D; Ng N; Graham LK; Mangiola S; Segelov E; Mahon K; Davis ID; Parente P; Pezaro C; Todenhöfer T; Horvath LG; Azad AA
Eur Urol Focus; 2021 Jan; 7(1):63-70. PubMed ID: 31103601
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of Germline DNA Repair Gene Mutations in De Novo Metastatic and Castration-Sensitive Prostate Cancer.
Wei Y; Wu J; Gu W; Wang J; Lin G; Qin X; Dai B; Gan H; Ye D; Zhu Y
Oncologist; 2020 Jul; 25(7):e1042-e1050. PubMed ID: 32190957
[TBL] [Abstract][Full Text] [Related]
17. Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer Registry.
Notohardjo JCL; Kuppen MCP; Westgeest HM; van Moorselaar RJA; Mehra N; Coenen JLLM; van Oort IM; de Vos AI; Vervenne WL; van den Bergh ACM; Aben KKH; Somford DM; Bergman AM; Uyl-de Groot CA; Gerritsen WR; van den Eertwegh AJM
Eur Urol Focus; 2021 Jul; 7(4):788-796. PubMed ID: 32362484
[TBL] [Abstract][Full Text] [Related]
18. Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis-Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer Setting.
Sayegh N; Tripathi N; Nussenzveig RH; Thomas VM; Tandar C; Goel D; Nordblad B; Sahu KK; Li H; L Maughan B; Agarwal N; Swami U
Eur Urol Focus; 2023 Jan; 9(1):106-109. PubMed ID: 35835693
[TBL] [Abstract][Full Text] [Related]
19. Age, Gleason Score, and PSA are important prognostic factors for survival in metastatic castration-resistant prostate cancer. Results of The Uroncor Group (Uro-Oncological Tumors) of the Spanish Society of Radiation Oncology (SEOR).
Valero J; Peleteiro P; Henríquez I; Conde A; Piquer T; Lozano A; Soler CC; Muñoz J; Illescas A; Jove J; Flores MM; Baquedano J; Diezhandino P; de Celis RP; Pardo EH; Samper P; Villoslada I; Eguiguren M; Millan V
Clin Transl Oncol; 2020 Aug; 22(8):1378-1389. PubMed ID: 31989474
[TBL] [Abstract][Full Text] [Related]
20. Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy.
Pond GR; Armstrong AJ; Wood BA; Leopold L; Galsky MD; Sonpavde G
BJU Int; 2012 Dec; 110(11 Pt B):E461-8. PubMed ID: 22520631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
